Final - June 17, 2019

page 1 of 2

PRESIDER/PRESENTER(s)

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

8:30 Human Papillomavirus Vaccines 

Introduction

Background 

9vHPV Immunogenicity and Safety Trial in Mid-Adult 

Females

Overview of Health Economic Models for HPV 

Vaccination of Mid-Adults

Evidence to Recommendations (EtR) Framework

Work Group Considerations and Proposed Policy 

Options

Dr. Peter Szilagyi (ACIP, WG Chair)

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Alain Luxembourg (Merck & Co.)

Dr. Harrell Chesson (CDC/NCHHSTP)

Dr. Elissa Meites (CDC/NCIRD)

Dr. Lauri Markowitz (CDC/NCIRD)

10:00 Break 

10:15 Pneumococcal Vaccines 

Introduction

Considerations for PCV13 use among adults 65 years or 

older and summary of the Evidence to 

Recommendations (EtR) Framework

Proposed policy options

Dr. Grace Lee (ACIP, WG Chair)

Dr. Almea Matanock (CDC/NCIRD)

Dr. Almea Matanock (CDC/NCIRD)

11:45 Lunch

1:00 Combination Vaccines 

Introduction

Summary and Relevant Evidence to Recommendation 

Information

Dr. Kelly Moore (ACIP, WG Chair)

Dr. Sara Oliver (CDC/NCIRD)

1:30 Public Comment 

2:10

2:25 VOTES 

Human Papillomavirus 

Pneumococcal Vaccines 

VFC VOTES

Diphtheria, Tetanus, & Pertussis

Haemophilus influenzae type b

Hepatitis B

Polio

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Almea Matanock (CDC/NCIRD)

Mr. Frank Whitlatch (CDC/NCIRD)

3:25 Break

3:40 Measles Update TBD

3:55 Zoster Vaccines

Introduction

Update: Safety Monitoring and Surveillance for 

Recombinant Zoster Vaccine (RZV)

Herpes Zoster Work Group Summary

Dr. Kelly Moore (ACIP, WG Chair)

Dr. Tom Shimabukuro (CDC/NCEZID)

Dr. Kathleen Dooling (CDC/NCIRD)

4:30 Pertussis Vaccines

Introduction

EtR Framework, Work Group Considerations and 

Proposed Policy Options

Dr. Henry Bernstein (ACIP, WG Chair)

Dr. Fiona Havers (CDC/NCIRD)

5:00 Rabies Vaccine Dr. Sharon Frey (ACIP, WG Chair)

5:10 Adjourn

Break

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329 

AGENDA ITEM

June 26-27, 2019

Wednesday, June 26

8:00 Welcome & Introductions

This document has been archived for historical purposes. (6/17/2019)
Final - June 17, 2019

page 2 of 2

8:30 Influenza Vaccines

Introduction

2018-19 U.S. Influenza Activity

2018-19 Influenza Vaccine Effectiveness

2018-19 Influenza Vaccine Safety

Proposed Recommendations for 2019-20 

Dr. Chip Walter (ACIP, WG Chair)

Ms. Lynette Brammer (CDC/NCIRD)

Dr. Brendan Flannery (CDC/NCIRD)

Dr. Tom Shimabukuro (CDC/NCEZID)

Dr. Lisa Grohskopf (CDC/NCIRD)

9:45 Break

10:00 Hepatitis A Vaccines 

Introduction

Proposed Recommendations for Use of Hepatitis A 

Dr. Kelly Moore (ACIP, WG Chair)

Dr. Noele Nelson (CDC/NCHHSTP)

11:15 Break

11:30 Meningococcal Vaccines

Introduction

Review of Immunogenicity and persistence data, 

GRADE, EtR, and policy options for MenB booster 

doses

Proposed recommendations for use of meningococcal 

vaccines

Dr. David Stephens (ACIP, WG Chair)

Dr. Sarah Mbaeyi (CDC/NCIRD)

Dr. Sarah Mbaeyi (CDC/NCIRD)

12:30 Lunch

1:30 Public Comment

2:10 VOTES & VFC VOTES 

Influenza Vaccines 

Influenza VFC

Hepatitis A Vaccines 

Hepatitis A 

Meningococcal Vaccines 

Meningococcal VFC

Dr. Lisa Grohskopf (CDC/NCIRD)

Mr. Frank Whitlatch (CDC/NCIRD)

Dr. Noele Nelson (CDC/NCHHSTP)

Mr. Frank Whitlatch (CDC/NCIRD)

Dr. Sarah Mbaeyi (CDC/NCIRD)

Mr. Frank Whitlatch (CDC/NCIRD)

2:55 Break

3:10 Dengue Vaccine

Introduction

Dengue Epidemiology in the U.S. 

Dengvaxia Phase III Clinical Trials and Long Term Follow 

Up

Work Group Considerations and Next Steps

Dr. Robert Atmar (ACIP, WG Chair)

Dr. Gabriela Paz-Bailey (CDC, NCEZID)

Dr. Gustavo Dayan (Sanofi Pasteur)

Dr. Steve Waterman (CDC, NCEZID)

4:10 Adjourn

Acronyms

AI/AN

AVA

CDC

CMS

DoD

DVA

EtR

FDA

GRADE

Hib

HRSA

IHS

MenB

NCHHSTP

NCIRD

NCEZID

NVPO

PCV13

RZV

WG

American Indian/Alaska Native 

Anthrax vaccine absorbed

Centers for Disease Control & Prevention

Centers for Medicare and Medicaid Services 

Department of Defense

Department of Veterans Affairs

Evidence to Recommendations Framework

Food and Drug Administration

Grading of Recommendations Assessment, Development and Evaluation

Haemophilus influenzae type b

Health Resources and Services Administration

Indian Health Service

Serogroup B meningococcal vaccine

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

National Vaccine Program Office

13-valent pneumococcal conjugate vaccine 

Recombinant zoster vaccine

Work Group

Vaccine effectiveness

Thursday, June 27

8:00 Unfinished Business and Agency Updates

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

VE

This document has been archived for historical purposes. (6/17/2019)